TG-interacting factor 1 (Tgif1)-deficiency attenuates bone remodeling and blunts the anabolic response to parathyroid hormone
Parathyroid hormone (PTH) is used to treat osteoporosis, but its therapeutic mechanism remains unclear. Here, the authors show that Tgif1 is a PTH target gene, and that its deletion impairs the function of osteoblasts and PTH-induced bone formation in mice.
Guardado en:
Autores principales: | Hiroaki Saito, Andreas Gasser, Simona Bolamperti, Miki Maeda, Levi Matthies, Katharina Jähn, Courtney L. Long, Hartmut Schlüter, Marcel Kwiatkowski, Vaibhav Saini, Paola Divieti Pajevic, Teresita Bellido, Andre J. van Wijnen, Khalid S. Mohammad, Theresa A. Guise, Hanna Taipaleenmäki, Eric Hesse |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e1b46a452798403ebde7a78a57d3c849 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
TgIF2K-B Is an eIF2α Kinase in Toxoplasma gondii That Responds to Oxidative Stress and Optimizes Pathogenicity
por: Leonardo Augusto, et al.
Publicado: (2021) -
SIKs control osteocyte responses to parathyroid hormone
por: Marc N. Wein, et al.
Publicado: (2016) -
Loss of Tgif function causes holoprosencephaly by disrupting the SHH signaling pathway.
por: Kenichiro Taniguchi, et al.
Publicado: (2012) -
Premature senescence and increased TGFβ signaling in the absence of Tgif1.
por: Brad J Zerlanko, et al.
Publicado: (2012) -
Women's Experiences of Using Anabolic Androgenic Steroids
por: Annica Börjesson, et al.
Publicado: (2021)